Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis

Always check the ethics disclosures, but especially when a finding involves a new product. https://t.co/UqACsWaBhi

Article finds a new shot costing $14,000 is a cost-effective alternative to generic therapies. One author "reports personal fees from Nymox...as paid consultant and...a shareholder in Nymox, outside the submitted work." @BMC_series Industry 1, Science 0 h